Journal article
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation
Abstract
BACKGROUND: Whether the pattern of atrial fibrillation (AF) modifies the risk/benefit of anticoagulation is controversial. In ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or systemic embolic events and significantly reduced bleeding and cardiovascular mortality. …
Authors
Link MS; Giugliano RP; Ruff CT; Scirica BM; Huikuri H; Oto A; Crompton AE; Murphy SA; Lanz H; Mercuri MF
Journal
Circulation Arrhythmia and Electrophysiology, Vol. 10, No. 1,
Publisher
Wolters Kluwer
Publication Date
January 2017
DOI
10.1161/circep.116.004267
ISSN
1941-3149